[go: up one dir, main page]

WO2008030273A3 - Compositions and methods for diagnosis and treatment of type 2 diabetes - Google Patents

Compositions and methods for diagnosis and treatment of type 2 diabetes Download PDF

Info

Publication number
WO2008030273A3
WO2008030273A3 PCT/US2007/007875 US2007007875W WO2008030273A3 WO 2008030273 A3 WO2008030273 A3 WO 2008030273A3 US 2007007875 W US2007007875 W US 2007007875W WO 2008030273 A3 WO2008030273 A3 WO 2008030273A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
diagnosis
treatment
methods
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/007875
Other languages
French (fr)
Other versions
WO2008030273A2 (en
Inventor
Cohava Gelber
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Type Culture Collection ATCC
Original Assignee
American Type Culture Collection ATCC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07754400A priority Critical patent/EP2069768A4/en
Priority to AU2007293465A priority patent/AU2007293465A1/en
Priority to CA002661332A priority patent/CA2661332A1/en
Priority to JP2009526587A priority patent/JP2010502946A/en
Application filed by American Type Culture Collection ATCC filed Critical American Type Culture Collection ATCC
Priority to US11/901,925 priority patent/US20080300170A1/en
Publication of WO2008030273A2 publication Critical patent/WO2008030273A2/en
Publication of WO2008030273A3 publication Critical patent/WO2008030273A3/en
Priority to US12/319,883 priority patent/US20090203602A1/en
Anticipated expiration legal-status Critical
Priority to US12/496,180 priority patent/US7951776B2/en
Priority to US12/759,072 priority patent/US7951382B2/en
Priority to US12/776,601 priority patent/US20100267052A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes (Figure 21).
PCT/US2007/007875 2006-09-01 2007-03-28 Compositions and methods for diagnosis and treatment of type 2 diabetes Ceased WO2008030273A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP07754400A EP2069768A4 (en) 2006-09-01 2007-03-28 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
AU2007293465A AU2007293465A1 (en) 2006-09-01 2007-03-28 Compositions and methods for diagnosis and treatment of Type 2 Diabetes
CA002661332A CA2661332A1 (en) 2006-09-01 2007-03-28 Compositions and methods for diagnosis and treatment of type 2 diabetes
JP2009526587A JP2010502946A (en) 2006-09-01 2007-03-28 Compositions and methods for diagnosing and treating type 2 diabetes
US11/901,925 US20080300170A1 (en) 2006-09-01 2007-09-18 Compositions and methods for diagnosis and treatment for type 2 diabetes
US12/319,883 US20090203602A1 (en) 2006-09-01 2009-01-12 Compositions and methods for diagnosis and treatment of type 2 diabetes
US12/496,180 US7951776B2 (en) 2006-09-01 2009-07-01 Methods for treatment of type 1 diabetes
US12/759,072 US7951382B2 (en) 2006-09-01 2010-04-13 Methods for treatment of type 2 diabetes
US12/776,601 US20100267052A1 (en) 2006-09-01 2010-05-10 Compositions and methods for diagnosis and treatment of type 2 diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84171706P 2006-09-01 2006-09-01
US60/841,717 2006-09-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/901,925 Continuation-In-Part US20080300170A1 (en) 2006-09-01 2007-09-18 Compositions and methods for diagnosis and treatment for type 2 diabetes

Publications (2)

Publication Number Publication Date
WO2008030273A2 WO2008030273A2 (en) 2008-03-13
WO2008030273A3 true WO2008030273A3 (en) 2008-08-28

Family

ID=39157723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007875 Ceased WO2008030273A2 (en) 2006-09-01 2007-03-28 Compositions and methods for diagnosis and treatment of type 2 diabetes

Country Status (6)

Country Link
EP (1) EP2069768A4 (en)
JP (1) JP2010502946A (en)
CN (1) CN101563597A (en)
AU (1) AU2007293465A1 (en)
CA (1) CA2661332A1 (en)
WO (1) WO2008030273A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108872293A (en) * 2018-08-10 2018-11-23 厦门大学 A kind of metabonomic analysis of Alveolar echinococcosis and the construction method of preliminary screening model

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2010011860A1 (en) 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
US8168396B2 (en) * 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
JP5812701B2 (en) * 2010-06-23 2015-11-17 アークレイ株式会社 Method for measuring plasma glucose
WO2012000058A1 (en) * 2010-07-02 2012-01-05 Newsouth Innovations Pty Limited Inheritance of metabolic dysfunction
HRP20191713T1 (en) 2011-07-01 2019-12-27 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (en) 2012-11-28 2016-08-05 恩格姆生物制药公司 Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (en) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc FGF19 chimeric peptides for use in the treatment of bile acid disorders
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
MX375032B (en) 2014-01-24 2025-03-06 Ngm Biopharmaceuticals Inc BINDING PROTEINS AND METHODS OF USING THEM.
CN103969234B (en) * 2014-04-17 2017-02-15 山东东兴汇智生物科技有限公司 Luciferase- poly-antigen fusion protein and protein A agarose-fusion protein-antibody complex
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6949711B2 (en) 2014-10-23 2021-10-20 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Pharmaceutical composition containing peptide variant and method of use thereof
WO2016073855A1 (en) * 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA2998275A1 (en) * 2015-09-11 2017-03-16 Universidad De Los Andes In vitro method for identifying a pregnancy related disease
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
CN106906278A (en) * 2015-12-22 2017-06-30 复旦大学 Predict biomarker of type ii diabetes cardiovascular complication risk and application thereof
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
JP2018048962A (en) * 2016-09-23 2018-03-29 シスメックス株式会社 Method and device for assisting diagnosis of progression risk of diabetic nephropathy
US11378558B2 (en) * 2018-02-27 2022-07-05 Agency For Science, Technology And Research Methods, apparatus, and computer-readable media for glycopeptide identification
KR20210144809A (en) * 2019-03-28 2021-11-30 룬도흐 다이아그노스틱스 에이비 Use of follistatin in predicting type 2 diabetes risk
CN113539470A (en) * 2020-04-14 2021-10-22 郑州大学第一附属医院 A differential diagnosis prediction model and construction method of diabetic nephropathy and non-diabetic kidney disease
CN114487430A (en) * 2020-11-12 2022-05-13 首都医科大学附属北京世纪坛医院 Application of inter-urine-alpha-trypsin inhibitor heavy chain H4 protein and polypeptide fragment thereof in gestational diabetes
CN114404589B (en) * 2021-12-24 2023-06-30 浙江大学 Application of RNASE4 as drug target for treating and/or preventing diabetes
CN118879848B (en) * 2024-07-03 2025-04-18 南京医科大学眼科医院 A biomarker for diagnosing diabetic retinopathy, a detection kit and its application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224304A1 (en) * 2003-04-29 2004-11-11 Biostratum, Inc. ApoCIII and the treatment and diagnosis of diabetes
US20050054005A1 (en) * 2003-06-20 2005-03-10 Ellis Tamir M. Biomarkers for differentiating between type 1 and type 2 diabetes
EP1615035A1 (en) * 2004-07-07 2006-01-11 F.Hoffmann-La Roche Ag Multimarker panel for diabetes type 1 and 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121255A1 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Use of alpha 1-antichymotrypsin polypeptide or nucleic acids encoding the polypeptide, or of a cell expressing the polypeptide, or of antibody against the polypeptide, for diagnosing, treating or preventing poorly-healing wounds
CA2446197C (en) * 2001-04-30 2011-12-13 Switch Biotech Ag Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an act polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
IL160229A0 (en) * 2001-08-10 2004-07-25 Genset Sa Polynucleotides, polypeptides encoded thereby and their use
JP2003235573A (en) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd Diabetic nephropathy marker and its use
JPWO2004084797A1 (en) * 2003-02-28 2006-06-29 ヒュ—ビット ジェノミクス株式会社 Type 2 diabetes-related genes and their use
JP2005337952A (en) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc Lifestyle-related disease predictive factors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224304A1 (en) * 2003-04-29 2004-11-11 Biostratum, Inc. ApoCIII and the treatment and diagnosis of diabetes
US20050054005A1 (en) * 2003-06-20 2005-03-10 Ellis Tamir M. Biomarkers for differentiating between type 1 and type 2 diabetes
EP1615035A1 (en) * 2004-07-07 2006-01-11 F.Hoffmann-La Roche Ag Multimarker panel for diabetes type 1 and 2

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUDDE ET AL.: "Peptidomics Biomarker Discovery in Mouse Models of Obesity and Type 2 Diabetes", COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol. 8, 2005, pages 775 - 781, XP008137903 *
HU ET AL.: "Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women", DIABETES, vol. 53, March 2004 (2004-03-01), pages 693 - 700, XP008108534 *
MEIGS J.B. ET AL.: "Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus", JAMA, vol. 291, no. 16, April 2004 (2004-04-01), pages 1978 - 1986, XP008061596 *
MISCHAK H. ET AL.: "Proteomic analysis for the assessment of diabetic renal damage in humans", CLINICAL SCIENCE, vol. 107, 2004, pages 485 - 495, XP002397415 *
See also references of EP2069768A4 *
STEFAN ET AL.: "Alpha2-Heremans-Schmid Glycoprotein/Fetuin-A is Associated with Insulin in the Liver in Humans", DIABETES CARE, vol. 29, no. 4, April 2006 (2006-04-01), pages 853 - 857, XP008108541 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108872293A (en) * 2018-08-10 2018-11-23 厦门大学 A kind of metabonomic analysis of Alveolar echinococcosis and the construction method of preliminary screening model

Also Published As

Publication number Publication date
JP2010502946A (en) 2010-01-28
AU2007293465A1 (en) 2008-03-13
EP2069768A2 (en) 2009-06-17
WO2008030273A2 (en) 2008-03-13
CN101563597A (en) 2009-10-21
CA2661332A1 (en) 2008-03-13
EP2069768A4 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
MY153198A (en) Inhibitors of protein aggregation
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2007022518A3 (en) New uses of glucoregulatory proteins
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2010124101A3 (en) Genetic markers associated with endometriosis and use thereof
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
WO2010033951A3 (en) Methods for identification and prediction of multiple sclerosis disease and therapy response
WO2007147868A3 (en) Prevention of muscle atrophy
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2009016231A3 (en) Compositions and methods for detecting histamine related disorders
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780040768.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754400

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2661332

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009526587

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007293465

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007754400

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007293465

Country of ref document: AU

Date of ref document: 20070328

Kind code of ref document: A